You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Clinical characteristics

From: Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

  All Casesa Pre-ipi approval Post-ipi approval Post-ipi approval
(n = 300) (n = 94) (n = 206) (n = 206)
ICI Treated ICI Not Treated
Age at initial cutaneous melanoma diagnosis (Years, %)     (n = 160) (n = 46)
  < 30 9 (03.0) 5 (05.3) 4 (01.9) 2 (01.3) 2 (04.3)
 30–39 25 (08.3) 11 (11.7) 14 (06.8) 9 (05.6) 5 (10.9)
 40–49 49 (16.3) 15 (16.0) 34 (16.5) 26 (16.3) 8 (17.4)
 50–59 69 (23.0) 25 (26.6) 44 (21.4) 37 (23.1) 7 (15.2)
 60–69 68 (22.7) 17 (18.1) 51 (24.8) 40 (25.0) 11 (23.9)
 70–79 51 (17.0) 13 (13.8) 38 (18.4) 31 (19.4) 7 (15.2)
  ≥ 80 29 (09.7) 8 (08.5) 21 (10.2) 15 (09.4) 6 (13.0)
 Mean 59 56 60 61 58
Year of diagnosis (Range) 1974–2016 1974–2010 1989–2016 1990–2016 1989–2016
Sex
 Female 111 (37.0) 36 (38.3) 75 (36.4) 53 (33.1) 22 (47.8)
 Male 189 (63.0) 58 (61.7) 131 (63.6) 107 (66.9) 24 (52.2)
Race
 White 293 (97.7) 94 (100.0) 199 (96.6) 154 (96.3) 45 (97.8)
 Other 2 (06.0) 0 (00.0) 2 (01.0) 1 (00.6) 1 (02.2)
 Unknown 5 (01.7) 0 (00.0) 5 (02.4) 5 (03.1) 0 (00.0)
Vital status at last follow up
 Alive 136 (45.3) 16 (17.0) 120 (58.3) 92 (57.5) 28 (60.9)
 Dead 164 (54.7) 78 (83.0) 86 (41.7) 68 (42.5) 18 (39.1)
Year of bx proven Stage IV disease (range) 1992–2017 1992–2011 2011–2017 2011–2017 2011–2017
Months of follow up (Median)b 16.2 16.5 16.2 16.2 15.5
  < 1 13 (04.3) 0 (00.0) 13 (06.3) 10 (06.3) 3 (06.5)
 3 122 (40.7) 0 (00.0) 122 (59.2) 104 (65.0) 18 (39.1)
 6 74 (24.7) 3 (03.2) 71 (34.5) 46 (28.8) 25 (54.3)
 10 42 (14.0) 42 (44.7) 0 (00.0) 0 (00.0) 0 (00.0)
  > 10 49 (16.3) 49 (52.1) 0 (00.0) 0 (00.0) 0 (00.0)
 Median 4.4 10 3 2.8 4.2
Years from diagnosis to bx proven Stage IV disease (Median) 1.1 1.5 1 1 0.7
Received BRAF TKI (Yes, %) 25 (08.3) 0 (00.0) 25 (12.1) 19 (11.9) 6 (13.0)
Mo from specimen collection to BRAF TKI (Median) 6·5 N/A 6·5 8 6
Checkpoint inhibitor
 Ipilimumab   72 (45.0) N/A
 Pembrolizumab   68 (42.5) N/A
 Nivolumab   7 (04.4) N/A
 Ipilimumab + Nivolumab   13 (08.1) N/A
Time to progression (median days)   77.5 N/A
Progression free survival (median days)   129.5 N/A
  1. aAll cases are metastatic and no cutaneous samples included. bFor pre-ipi approval patients follow-up is the number of months from date of specimen collection (bx proven Stage IV disease) to last date of follow up or date of death, and for post-ipi approval patients represents the number of months from date of first dose of checkpoint inhibitor to last date of follow up or date of death